Determination of Regulatory Review Period for Purposes of Patent Extension; PIQRAY

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for PIQRAY, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to the submission of patent extension applications to the U.S. Patent and Trademark Office (USPTO), Department of Commerce.